{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:43:36Z","timestamp":1790102616383,"version":"4.0.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.phrs.2019.01.037","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T19:33:00Z","timestamp":1548271980000},"page":"501-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Intriguing relationship between antihypertensive therapy and cancer"],"prefix":"10.1016","volume":"141","author":[{"given":"Marijana","family":"Tadic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Cuspidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Belyavskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0005","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex. Heart Inst. J."},{"issue":"29","key":"10.1016\/j.phrs.2019.01.037_bib0010","doi-asserted-by":"crossref","first-page":"20855","DOI":"10.18632\/oncotarget.25024","article-title":"Hypertension in malignancy\u2013an underappreciated problem","volume":"9","author":"Ma\u0142yszko","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0015","first-page":"246","article-title":"Hypertension in patients with cancer","volume":"104","author":"Barbosa de Souza","year":"2015","journal-title":"Arq. Bras. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2014.08.004","article-title":"Hypertension induced by chemotherapeutic and immunosuppressive agents: a new challenge","volume":"93","author":"Abi Aad","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.phrs.2019.01.037_bib0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40264-017-0599-x","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"41","author":"Tang","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2019.01.037_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","article-title":"Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis","volume":"122","author":"Gandini","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.phrs.2019.01.037_bib0035","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","article-title":"Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-medicare population","volume":"26","author":"Chen","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"November (15)","key":"10.1016\/j.phrs.2019.01.037_bib0040","article-title":"Calcium channel blockers and the risk for lung cancer: a population-based nested case-control study","author":"Rotshild","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2019.01.037_bib0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ijc.30066","article-title":"Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer","volume":"139","author":"Huang","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2019.01.037_bib0050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1158\/1055-9965.EPI-08-0936","article-title":"Risk of endometrial cancer in relation to medical conditions and medication use","volume":"18","author":"Fortuny","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0055","first-page":"289","article-title":"Antihypertensive medication use and risk of renal cell carcinoma","volume":"28","author":"Colt","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"8","key":"10.1016\/j.phrs.2019.01.037_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7080197","article-title":"Anti-hypertensive medication use, soluble receptor for glycation end products and risk of pancreatic cancer in the Women\u2019s Health Initiative Study","volume":"7","author":"Wang","year":"2018","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2019.01.037_bib0070","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer","volume":"17","author":"Assimes","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"37","key":"10.1016\/j.phrs.2019.01.037_bib0075","doi-asserted-by":"crossref","first-page":"62545","DOI":"10.18632\/oncotarget.19117","article-title":"Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijc.30717","article-title":"Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: results from a population-based study","volume":"141","author":"Jansen","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0090","article-title":"Renin-angiotensin system blockade for the risk of cancer and death","volume":"17","author":"Shen","year":"2016","journal-title":"J. Renin. Syst."},{"issue":"17","key":"10.1016\/j.phrs.2019.01.037_bib0095","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jnci\/djn262","article-title":"VATTC Trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancerprevention in the randomized VATTC trial","volume":"100","author":"Christian","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"13","key":"10.1016\/j.phrs.2019.01.037_bib0100","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","article-title":"Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma","volume":"77","author":"Udumyan","year":"2017","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.phrs.2019.01.037_bib0105","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/cncr.29392","article-title":"Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer","volume":"121","author":"Watkins","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2019.01.037_bib0110","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.01.037_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159672","article-title":"The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain Study","volume":"11","author":"G\u00f3mez-Acebo","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.phrs.2019.01.037_bib0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12894-018-0318-7","article-title":"Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies","volume":"18","author":"Cao","year":"2018","journal-title":"BMC Urol."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10641963.2017.1288736","article-title":"Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies","volume":"40","author":"Zhao","year":"2018","journal-title":"Clin. Exp. Hypertens."},{"issue":"13","key":"10.1016\/j.phrs.2019.01.037_bib0135","doi-asserted-by":"crossref","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Evidence from a meta-analysis including 55 studies","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0140","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the Rotterdam Study","volume":"112","author":"van der Knaap","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2019.01.037_bib0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/cs1000481","article-title":"Angiotensin receptors: distribution, signalling and function","volume":"100","author":"Dinh","year":"2001","journal-title":"Clin. Sci. (Lond)."},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","article-title":"Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer","volume":"2","author":"Escobar","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"16","key":"10.1016\/j.phrs.2019.01.037_bib0155","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.01.037_bib0160","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1096\/fj.03-0129com","article-title":"Diff erential regulation of in vivo angiogenesis by angiotensin II receptors","volume":"17","author":"Walther","year":"2003","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.phrs.2019.01.037_bib0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2019.01.037_bib0170","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archinte.160.3.349","article-title":"Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer","volume":"160","author":"Meier","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.01.037_bib0180","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years","volume":"98","author":"Li","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/HJH.0000000000000813","article-title":"Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study","volume":"34","author":"Chang","year":"2016","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2016.375","article-title":"The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer","volume":"116","author":"Mandilaras","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"August (15)","key":"10.1016\/j.phrs.2019.01.037_bib0195","article-title":"Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland- A nationwide cohort study","author":"Santala","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2019.01.037_bib0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5414\/CNP73439","article-title":"Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients","volume":"73","author":"Moscarelli","year":"2010","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.phrs.2019.01.037_bib0205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/apt.14388","article-title":"Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study","volume":"47","author":"Busby","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"22","key":"10.1016\/j.phrs.2019.01.037_bib0210","doi-asserted-by":"crossref","first-page":"e887","DOI":"10.1097\/MD.0000000000000887","article-title":"Renin-angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib","volume":"94","author":"Aydiner","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.phrs.2019.01.037_bib0215","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2093::AID-CNCR1>3.0.CO;2-E","article-title":"Effects of calcium channel blockers on cellular apoptosis","volume":"85","author":"Mason","year":"1999","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2019.01.037_bib0220","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/11592780-000000000-00000","article-title":"Drug-induced photosensitivity: culprit drugs, management and prevention","volume":"34","author":"Drucker","year":"2011","journal-title":"Drug Saf."},{"issue":"16","key":"10.1016\/j.phrs.2019.01.037_bib0225","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinternmed.2012.2754","article-title":"Antihypertensive drugs and lip cancer in non-Hispanic whites","volume":"172","author":"Friedman","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.01.037_bib0230","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40264-018-0644-4","article-title":"The risk for lung cancer incidence with calcium channel blockers: a systematic review and meta-analysis of observational studies","volume":"41","author":"Rotshild","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2019.01.037_bib0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijcard.2014.10.028","article-title":"The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study","volume":"179","author":"Wong","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0240","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/EDE.0000000000000483","article-title":"Use of calcium channel blockers and risk of breast cancer: a population-based cohort study","volume":"27","author":"Azoulay","year":"2016","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women","volume":"18","author":"Wilson","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"February (1)","key":"10.1016\/j.phrs.2019.01.037_bib0250","article-title":"Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study","author":"Busby","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2019.01.037_bib0255","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"7-8","key":"10.1016\/j.phrs.2019.01.037_bib0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18632\/oncoscience.357","article-title":"Beta-adrenergic receptors are expressed across diverse cancers","volume":"4","author":"Rains","year":"2017","journal-title":"Oncoscience"},{"key":"10.1016\/j.phrs.2019.01.037_bib0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbi.2016.06.011","article-title":"\u03b22-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer","volume":"57","author":"Chang","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"18","key":"10.1016\/j.phrs.2019.01.037_bib0270","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0275","article-title":"The beta2-adrenoceptor activates a positive cAMP-calcium feed forward loop to drive breast cancer cell invasion","volume":"30","author":"Pon","year":"2016","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"issue":"5","key":"10.1016\/j.phrs.2019.01.037_bib0285","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000455143","article-title":"Is beta-blocker use beneficial in breast cancer? A meta-analysis","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.phrs.2019.01.037_bib0290","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"\u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijc.30717","article-title":"Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: results from a population-based study","volume":"141","author":"Jansen","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0300","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic \u03b2-blocker use and lung cancer survival: a population-based cohort study","volume":"7","author":"Weberpals","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-016-0782-5","article-title":"Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts","volume":"18","author":"Cardwell","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2019.01.037_bib0310","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10641963.2017.1288736","article-title":"Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: \u2009Evidence from observational studies","volume":"40","author":"Zhao","year":"2018","journal-title":"Clin. Exp. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0320","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.30062","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis","volume":"139","author":"Raimondi","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"13","key":"10.1016\/j.phrs.2019.01.037_bib0325","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","article-title":"Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma","volume":"77","author":"Udumyan","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.01.037_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","article-title":"Beta-blockers and cancer prognosis \u2013 the role of immortal time bias: a systematic review and meta-analysis","volume":"47","author":"Weberpals","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.01.037_bib0335","first-page":"12","article-title":"Photosensitivity: light, sun and pharmacy","volume":"16","author":"Zammit","year":"2010","journal-title":"J. Malta Coll. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0340","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/phpp.12085","article-title":"Photosensitizing medications and photocarcinogenesis","volume":"30","author":"O\u2019Gorman","year":"2014","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"26","key":"10.1016\/j.phrs.2019.01.037_bib0345","doi-asserted-by":"crossref","first-page":"e4070","DOI":"10.1097\/MD.0000000000004070","article-title":"Risk of skin cancer in patients with diabetes mellitus: a nationwide retrospective cohort study in Taiwan","volume":"95","author":"Tseng","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.phrs.2019.01.037_bib0350","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11154-016-9393-9","article-title":"Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer","volume":"17","author":"Karimi","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of non-melanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.01.037_bib0360","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/joim.12629","article-title":"Hydrochlorothiazide use is strongly associated with risk of lip cancer","volume":"282","author":"Potteg\u00e5rd","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.01.037_bib0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11892-007-0031-5","article-title":"Antihypertensive agents, insulin sensitivity, and new-onset diabetes","volume":"7","author":"Sarafidis","year":"2007","journal-title":"Curr. Diab. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2019.01.037_bib0370","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2019.01.037_bib0375","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/ijc.28823","article-title":"Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women\u2019s Health Initiative","volume":"135","author":"Brasky","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2019.01.037_bib0380","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/ijc.31632","article-title":"Inhaled corticosteroids in COPD and the risk of lung cancer","volume":"143","author":"Lee","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2019.01.037_bib0385","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.phrs.2019.01.037_bib0390","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","article-title":"Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies","volume":"18","author":"Qiao","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181832084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181832084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:01:12Z","timestamp":1760911272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181832084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":78,"alternative-id":["S104366181832084X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.037","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intriguing relationship between antihypertensive therapy and cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}